Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!




January 23 - 25 2015, 12:00 AM - 12:00 AM


February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit



December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter


FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur


FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled


Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled



Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Comment Letter on Draft Blueprint for Prescriber Education Under Opioid REMS

Wednesday, December 07, 2011

On December 7, ASA submitted comments to the Food and Drug Administration (FDA) in response to a Federal Register notice seeking input on a draft Blueprint that provides core messages for continuing education (CE) providers as they develop educational materials to train prescribers on long-acting and extended-release opioids (LA/ER).  This educational program is required by the class-wide Risk Evaluation and Mitigation Strategy (REMS) for LA/ER opioids, one step in the federal government’s action plan to combat prescription drug abuse.  The prescriber education program will be voluntary and should be provided without cost to health care professionals.  According to the draft Blueprint, the prescriber education program will include information on why prescriber education on LA/ER opioids is important, assessing patients for treatment, initiating therapy, modifying dosing, and discontinuing use, managing therapy, counseling patients about safe use, and general and specific drug information for LA/ER opioid products.  In the comment letter, ASA offered recommendations for revising the Blueprint and reiterated concerns we identified in our June 30, 2009 comment letter to the FDA on REMS for certain opioid drugs.   

According to the FDA, REMS is a “risk management plan that FDA can require a drug company to develop and implement to manage serious risks associated with a drug.”  Under the Food and Drug Administration Amendments Act of 2007, the FDA may require a manufacturer to develop and implement REMS when the FDA finds it is necessary to ensure that the benefits of a drug outweigh its risks.  All REMS include a timetable for submission of assessments of the strategy, and may also include a Medication Guide, communication plan, other elements to assure safe use of the drug, and an implementation system.  The REMS for LA/ER opioids, in addition to the voluntary prescriber education program, will include a timetable for submission of assessments, a Medication Guide, and materials that prescribers can use to educate patients.

Read the comments ASA submitted to FDA on the draft Blueprint.

Read FDA’s Federal Register notice and draft Blueprint.

Go to ASA’s Pain Medicine advocacy webpage to learn what federal policymakers are doing to combat prescription drug abuse.

« Back to Washington Alerts